Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant

Out-patient treatment is a viable option

S. Seropian, R. Nadkarni, Anand Jillella, E. Salloum, B. Burtness, G. L. Hu, D. Zelterman, D. L. Cooper

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

A retrospective analysis was performed on 100 patients with non-Hodgkin's lymphoma (NHL, n = 75) or Hodgkin's disease (HD, n = 25) who underwent peripheral blood progenitor cell transplant (PBPCT) following high-dose chemotherapy (HDCT) with BCNU, etoposide, cytarabine and melphalan (BEAM) between March 1994 and June 1997. Following PBPCT and until engraftment all patients received oral ciprofloxacin and fluconazole, patients with positive Herpes simplex virus serology received acyclovir and 91 patients received filgrastim. The median days of neutropenia and days to an absolute neutrophil count (ANC) > 500/mm3 were 6 and 9, respectively. Febrile neutropenia occurred in 68 patients, Gram-positive bacteremia occurred in 14 patients. No gram-negative infections, invasive fungal infections, intensive care visits or deaths occurred during the period of neutropenia or in the first 30 days following transplant. In multivariate logistic regression the risk of development of any infection was associated only with the duration of neutropenia (P = 0.02) and the risk of bacteremia was associated only with the number of CD34+ cells infused (P = 0.046). Among 49 patients treated in the outpatient setting, 14 (28%) were never admitted. High-dose chemotherapy with BEAM supported by PBPCT, prophylactic antibiotics and filgrastim resulted in a low incidence of infections and no acute mortality. WBC engraftment occurred rapidly allowing for a predictable course during which lengthy hospital stays and amphotericin therapy could be avoided.

Original languageEnglish (US)
Pages (from-to)599-605
Number of pages7
JournalBone Marrow Transplantation
Volume23
Issue number6
DOIs
StatePublished - Jan 1 1999

Fingerprint

Carmustine
Melphalan
Cytarabine
Etoposide
Hodgkin Disease
Non-Hodgkin's Lymphoma
Blood Cells
Outpatients
Stem Cells
Transplants
Drug Therapy
Infection
Neutropenia
Bacteremia
Therapeutics
Febrile Neutropenia
Acyclovir
Fluconazole
Amphotericin B
Simplexvirus

Keywords

  • Autologous stem cell transplantation
  • Infection
  • Neutropenia

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant : Out-patient treatment is a viable option. / Seropian, S.; Nadkarni, R.; Jillella, Anand; Salloum, E.; Burtness, B.; Hu, G. L.; Zelterman, D.; Cooper, D. L.

In: Bone Marrow Transplantation, Vol. 23, No. 6, 01.01.1999, p. 599-605.

Research output: Contribution to journalArticle

@article{5bbbf5df9b9b44f1a5520c2c99e89709,
title = "Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: Out-patient treatment is a viable option",
abstract = "A retrospective analysis was performed on 100 patients with non-Hodgkin's lymphoma (NHL, n = 75) or Hodgkin's disease (HD, n = 25) who underwent peripheral blood progenitor cell transplant (PBPCT) following high-dose chemotherapy (HDCT) with BCNU, etoposide, cytarabine and melphalan (BEAM) between March 1994 and June 1997. Following PBPCT and until engraftment all patients received oral ciprofloxacin and fluconazole, patients with positive Herpes simplex virus serology received acyclovir and 91 patients received filgrastim. The median days of neutropenia and days to an absolute neutrophil count (ANC) > 500/mm3 were 6 and 9, respectively. Febrile neutropenia occurred in 68 patients, Gram-positive bacteremia occurred in 14 patients. No gram-negative infections, invasive fungal infections, intensive care visits or deaths occurred during the period of neutropenia or in the first 30 days following transplant. In multivariate logistic regression the risk of development of any infection was associated only with the duration of neutropenia (P = 0.02) and the risk of bacteremia was associated only with the number of CD34+ cells infused (P = 0.046). Among 49 patients treated in the outpatient setting, 14 (28{\%}) were never admitted. High-dose chemotherapy with BEAM supported by PBPCT, prophylactic antibiotics and filgrastim resulted in a low incidence of infections and no acute mortality. WBC engraftment occurred rapidly allowing for a predictable course during which lengthy hospital stays and amphotericin therapy could be avoided.",
keywords = "Autologous stem cell transplantation, Infection, Neutropenia",
author = "S. Seropian and R. Nadkarni and Anand Jillella and E. Salloum and B. Burtness and Hu, {G. L.} and D. Zelterman and Cooper, {D. L.}",
year = "1999",
month = "1",
day = "1",
doi = "10.1038/sj.bmt.1701610",
language = "English (US)",
volume = "23",
pages = "599--605",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant

T2 - Out-patient treatment is a viable option

AU - Seropian, S.

AU - Nadkarni, R.

AU - Jillella, Anand

AU - Salloum, E.

AU - Burtness, B.

AU - Hu, G. L.

AU - Zelterman, D.

AU - Cooper, D. L.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - A retrospective analysis was performed on 100 patients with non-Hodgkin's lymphoma (NHL, n = 75) or Hodgkin's disease (HD, n = 25) who underwent peripheral blood progenitor cell transplant (PBPCT) following high-dose chemotherapy (HDCT) with BCNU, etoposide, cytarabine and melphalan (BEAM) between March 1994 and June 1997. Following PBPCT and until engraftment all patients received oral ciprofloxacin and fluconazole, patients with positive Herpes simplex virus serology received acyclovir and 91 patients received filgrastim. The median days of neutropenia and days to an absolute neutrophil count (ANC) > 500/mm3 were 6 and 9, respectively. Febrile neutropenia occurred in 68 patients, Gram-positive bacteremia occurred in 14 patients. No gram-negative infections, invasive fungal infections, intensive care visits or deaths occurred during the period of neutropenia or in the first 30 days following transplant. In multivariate logistic regression the risk of development of any infection was associated only with the duration of neutropenia (P = 0.02) and the risk of bacteremia was associated only with the number of CD34+ cells infused (P = 0.046). Among 49 patients treated in the outpatient setting, 14 (28%) were never admitted. High-dose chemotherapy with BEAM supported by PBPCT, prophylactic antibiotics and filgrastim resulted in a low incidence of infections and no acute mortality. WBC engraftment occurred rapidly allowing for a predictable course during which lengthy hospital stays and amphotericin therapy could be avoided.

AB - A retrospective analysis was performed on 100 patients with non-Hodgkin's lymphoma (NHL, n = 75) or Hodgkin's disease (HD, n = 25) who underwent peripheral blood progenitor cell transplant (PBPCT) following high-dose chemotherapy (HDCT) with BCNU, etoposide, cytarabine and melphalan (BEAM) between March 1994 and June 1997. Following PBPCT and until engraftment all patients received oral ciprofloxacin and fluconazole, patients with positive Herpes simplex virus serology received acyclovir and 91 patients received filgrastim. The median days of neutropenia and days to an absolute neutrophil count (ANC) > 500/mm3 were 6 and 9, respectively. Febrile neutropenia occurred in 68 patients, Gram-positive bacteremia occurred in 14 patients. No gram-negative infections, invasive fungal infections, intensive care visits or deaths occurred during the period of neutropenia or in the first 30 days following transplant. In multivariate logistic regression the risk of development of any infection was associated only with the duration of neutropenia (P = 0.02) and the risk of bacteremia was associated only with the number of CD34+ cells infused (P = 0.046). Among 49 patients treated in the outpatient setting, 14 (28%) were never admitted. High-dose chemotherapy with BEAM supported by PBPCT, prophylactic antibiotics and filgrastim resulted in a low incidence of infections and no acute mortality. WBC engraftment occurred rapidly allowing for a predictable course during which lengthy hospital stays and amphotericin therapy could be avoided.

KW - Autologous stem cell transplantation

KW - Infection

KW - Neutropenia

UR - http://www.scopus.com/inward/record.url?scp=0032981810&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032981810&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1701610

DO - 10.1038/sj.bmt.1701610

M3 - Article

VL - 23

SP - 599

EP - 605

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 6

ER -